Sarcomatoid carcinoma of lung- rare but dangerous histology - A case series

 

 

REFERENCES

1. Huang S, Shen S, Li X. Pulmonary sarcomatoid carcinoma: A clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol [Internet]. 2013;11(1):1. Available from: World Journal of Surgical Oncology
2. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol [Internet]. 2015;10(9):1243–60.
3. Karim NA, Schuster J, Eldessouki I, Gaber O, Namad T, Wang J, et al. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget [Internet]. 2018;9(3):4102–8.
4. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive cases. Hum Pathol [Internet]. 1985 Jun 1 [cited 2018 Aug 28];16(6):569–79.
5. Shen X, Lin Z, Lin Q, Ruan Z, Huang H. Pulmonary sarcomatoid carcinoma : a case report. 2013;17(2):210–3.
6. Ram R, Saadat P, Peng D, Vadmal M. Case report and literature review: primary cutaneous carcinosarcoma. Ann Clin Lab Sci [Internet]. 2005;35(2):189–94.
7. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134(11):1645–58.
8. Franks TJ, Galvin JR. Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med [Internet]. 2010;134(1):49–54.
9. Roesel C, Terjung S, Weinreich G, Hager T, Chalvatzoulis E, Metzenmacher M, et al. Sarcomatoid carcinoma of the lung: A rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interact Cardiovasc Thorac Surg. 2017;24(3):407–13.
10. Vieira T, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol [Internet]. 2013;8(12):1574–7.
11. Tamura Y, Fujiwara Y, Yamamoto N, Nokihara H, Horinouchi H, Kanda S, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma Cancer. BMC Res Notes. 2015;8(1):1–7.
12. Mountain CF. special report Revisions in the International System for Staging Lung Cancer *. Chest [Internet]. 1997;111(6):1710–7.
13. Group NMC. Adjuvant chemotherapy , with or without postoperative radiotherapy , in operable non-small-cell lung cancer : two meta-analyses of individual patient data. Lancet [Internet]. 1965;375(9722):1267–77.
14. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802.
15. Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, et al. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCartaTM Panel: Exploring therapeutic targets. Ann Oncol. 2015;26(8):1748–53.
16. Rangachari D, Kobayashi SS, Huberman MS. HHS Public Access. Lung Cancer. 2016;90(3):369–74.
17. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2015;373(17):1627–39.
18. Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer [Internet]. 2016;98:51–8.
19. Chang, Y. L. , Y. C. Lee , J. Y. Shih , and C. T. Wu . Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer 2001. 34 1:91–97
20. Koss, M. N. , L. Hochholzer , and T. O'Leary . Pulmonary blastomas. Cancer 1991. 67 9:2368–2381.
21. Pelosi, G. , A. Sonzogni , T. De Pas , et al. Pulmonary sarcomatoid carcinomas: a practical overview. Int J SurgPathol 2010. 18 (2):103–120.            
22. Mochizuki, T. , G. Ishii , K. Nagai , et al. Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J SurgPathol 2008. 32 (11):1727–1735.
23. Rossi, G. , A. Cavazza , N. Sturm , et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J SurgPathol 2003. 27 (3):311–324.
24. Wick, M. R. and P. E. Swanson . Carcinosarcomas: current perspectives and an historical review of nosological concepts. Semin Diagn Pathol 1993. 10 2:118–127.
25. Hartel, P. H. , J. C. Fanburg-Smith , and A. A. Frazier . et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol 2007. 20 7:760–769.
26. Ishida T, Tateishi M, Kaneko S, et al. Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg. 1990; 100(6):844–52.
27. Addis BJ, Corrin B. Pulmonary blastoma, carcinosarcoma and spindle-cell carcinoma: An immunohistochemical study of keratin intermediate filaments. J Pathol. 1985;147(4):291–301.
28. Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery 2012; 152: 397–402.